T4

T4 Dragon Pharma — Overview

T4 Dragon Pharma is levothyroxine sodium — thyroxine, the primary thyroid prohormone — at 50 mcg per tablet, supplied in packs of 100 tabs. T4 is not directly active at the receptor level: it must first be converted to triiodothyronine (T3) by peripheral deiodinase enzymes (D1 and D2) before binding thyroid hormone receptors and producing metabolic effects. This conversion step makes T4 inherently more gradual and forgiving than direct T3 administration — peak metabolic effect builds over one to two weeks as tissue conversion reaches steady state, and the seven-day plasma half-life means blood levels remain stable with once-daily dosing and fluctuate minimally if a dose is delayed.

In performance and physique contexts, T4 is used during cutting phases where sustained, controlled metabolic acceleration is the goal without the sharp cardiovascular and catabolic responses that can accompany aggressive T3 protocols. steroidwarehouse.com carries the Dragon Pharma 50 mcg tablet format, giving users a precise starting unit that matches the standard clinical tablet strength and supports gradual dose titration to individual response.

About the Compound: Levothyroxine (T4)

The healthy thyroid gland secretes primarily T4 (approximately 80% of total thyroid output) and a small amount of T3 directly. T4 circulates bound to thyroxine-binding globulin (TBG) and acts as the body's thyroid hormone reservoir. Its biological activity depends almost entirely on peripheral conversion: type I deiodinase (D1), concentrated in the liver, kidney, and thyroid, removes the outer-ring iodine atom from T4 to produce T3; type II deiodinase (D2), found in the pituitary, brain, and skeletal muscle, performs the same reaction with higher substrate affinity and is particularly relevant to muscle and CNS thyroid hormone availability. The result is that tissues regulate their own T3 supply by controlling local D1/D2 enzyme activity — a self-limiting mechanism that caps how much active T3 any given tissue receives from circulating T4.

• Conversion-gated activity — the core pharmacokinetic difference from T3 — because exogenous T4 must be converted before becoming active, tissue-level T3 availability rises gradually over days to weeks as deiodinase enzymes process the increasing T4 substrate load; this built-in delay prevents the abrupt spike in receptor activation that occurs when T3 is dosed directly; the catabolic and cardiovascular effects of thyroid hormone excess are correspondingly slower to develop and more readily managed by dose reduction before significant harm accumulates
• Seven-day plasma half-life — levothyroxine has one of the longest plasma half-lives of any orally administered hormone; blood levels are highly stable with once-daily dosing, and steady state is reached only after approximately 5–6 half-lives (roughly 5–6 weeks at a fixed dose); missing a single dose has negligible impact on serum levels; this pharmacokinetic stability is the primary reason T4 is more forgiving to use than T3, where the shorter 2.5-day half-life produces more pronounced troughs and sharper responses to missed doses
• Dose requirement is higher than T3 — because only approximately 20–30% of circulating T4 is converted to the active T3 form, and the remainder is converted to reverse T3 (rT3, a metabolically inactive isomer) or excreted, performance T4 doses of 100–200 mcg/day are needed to generate a metabolically meaningful increase in tissue T3 availability; this contrasts with direct T3 administration where 25–75 mcg/day typically achieves the same receptor-level effect
• Morning fasted administration is required — levothyroxine absorption is significantly impaired by food, calcium, iron, and some medications; taking T4 in a fed state reduces bioavailability by up to 40%; the standard protocol is to take the tablet 30–60 minutes before the first meal with a full glass of water; this is a practical point that directly affects dose consistency and therefore the linearity of metabolic response across the cycle
• HPT axis suppression and post-cycle recovery — exogenous T4 suppresses TSH via negative feedback on the hypothalamic-pituitary-thyroid axis, just as T3 does; however, the slow decline in serum T4 after the cycle ends (driven by the 7-day half-life) gives the HPT axis a more gradual opportunity to resume function; rebound hypothyroidism is less pronounced after T4 discontinuation than after abrupt T3 cessation, though a formal taper is still recommended to support a smooth recovery

What T4 Does

The metabolic effects of T4 are mediated entirely through its downstream conversion product, T3. Tissues that express high levels of D2 — particularly skeletal muscle, the pituitary, and the brain — convert T4 to T3 locally and achieve near-normal intracellular T3 concentrations even when serum T3 is modestly elevated. This tissue-regulated conversion means the thermogenic and anabolic/catabolic balance that results from T4 administration is more physiologically constrained than the effects seen with direct T3: the body's deiodinase capacity acts as a partial buffer against excess T3 receptor stimulation.

• Gradual basal metabolic rate elevation — as exogenous T4 raises circulating thyroxine levels, D1/D2 enzymes progressively convert the increased substrate to T3; resting energy expenditure rises over one to two weeks as tissue T3 concentrations build toward a new steady state; the increase in BMR at peak effect is comparable to that achievable with moderate T3 dosing, but the onset curve is slower and the effect ceiling is lower because peripheral conversion cannot fully replicate the receptor activation achieved by very high direct T3 doses
• Sustained fat oxidation without sharp dose-response peaks — the stability of T4 blood levels (7-day half-life, once-daily dosing) produces a consistently elevated substrate pool for deiodinase conversion throughout the day; there are no pronounced peaks or troughs in T3 availability as occur with the shorter T3 half-life; users typically report steadier thermogenesis, fewer acute cardiovascular surges, and more predictable fat loss progress across the cycle relative to equivalent-effect T3 dosing
• Preserved lean mass at moderate doses — the conversion-gated mechanism limits peak tissue T3 concentration relative to circulating T4 levels; at doses of 100–150 mcg/day, the net catabolic drive on skeletal muscle protein is meaningfully lower than with direct T3 at doses that produce equivalent thermogenesis; while an AAS base is still recommended for cycles above 150 mcg/day, the margin for error is wider than with T3 and the consequences of running T4 without an AAS base at moderate doses are less severe
• Cardiovascular and CNS effects are dose- and conversion-dependent — elevated heart rate, increased cardiac output, and thermogenic CNS symptoms (sweating, heat intolerance) emerge as tissue T3 levels rise from T4 conversion; at therapeutic and moderately supraphysiologic T4 doses these effects are substantially milder than the acute cardiovascular load of high-dose direct T3; at very high T4 doses (> 200 mcg/day) sufficient T3 can be generated from conversion to produce significant tachycardia and catabolic pressure, particularly when D1/D2 enzyme activity is upregulated by the high substrate load
• T3/T4 ratio modulation in stacked protocols — some advanced users run T4 as a base thyroid support compound alongside a small amount of direct T3 (25 mcg/day) to benefit from both the stable serum levels of T4 and the faster receptor activation of T3; T4 sustains the thyroid hormone pool while T3 provides the acute metabolic edge; this combination allows lower T3 doses to be used than would be required if T3 were the sole thyroid agent, reducing the catabolic and cardiovascular risk of the T3 component

Who It's For

• What sets T4 apart: T4's defining characteristic among thyroid-based fat loss agents is the conversion buffer — peripheral deiodinases regulate how much active T3 tissues actually produce from the T4 substrate, creating a self-limiting ceiling on receptor activation that direct T3 does not have; this makes T4 pharmacologically more forgiving: dose titration does not require the same precision as T3, missed doses do not produce acute troughs, and the cardiovascular and catabolic consequences of a dose that is slightly too high develop slowly enough to be caught and corrected before meaningful harm accumulates; the seven-day half-life also means the compound effectively self-tapers when discontinued, substantially reducing rebound hypothyroidism risk compared to abrupt T3 cessation
• Best scenario: intermediate to advanced users who want thyroid-mediated metabolic acceleration during a cutting cycle but have previously found T3 too harsh, too cardiovascularly demanding, or too unforgiving to dose precisely; athletes running longer cutting blocks of 8–12 weeks where the stability of T4 serum levels is a practical advantage over T3; users who prefer not to titrate doses week-by-week based on daily heart rate readings; advanced users who want to combine a T4 base with a low-dose T3 top-up to achieve a balanced thyroid hormone profile; users running GH-inclusive protocols where GH's ability to upregulate peripheral D2 activity enhances T4-to-T3 conversion and amplifies T4's metabolic effect
• Choose something else instead: users who need fast, precise, week-by-week adjustable fat loss in a defined short prep window (4–6 weeks) should choose T3 Dragon Pharma — T4 takes 1–2 weeks to reach effective metabolic output and cannot be rapidly up- or down-titrated the way T3 can; users not on an AAS base who want a non-catabolic fat loss agent should consider Clenbuterol Dragon Pharma, which supports thermogenesis through a mechanistically distinct pathway without thyroid axis involvement or the need for post-cycle recovery

T4 vs Alternatives

Combinations

Side Effects & Management

Monitoring

Taper & Recovery

T4 does not require SERMs or gonadotropins. The mandatory pharmacological consideration after a T4 cycle is HPT axis recovery. However, T4's 7-day half-life provides a built-in biological taper: even when dosing stops completely, serum levothyroxine declines gradually over 4–6 weeks as the body clears the remaining compound at the natural half-life rate. This makes the rebound hypothyroidism risk after T4 cycles substantially lower than after T3 cycles, where abrupt cessation causes a rapid drop in circulating T3 that the suppressed HPT axis cannot immediately compensate for.

Practical Summary

T4 Dragon Pharma occupies a distinct position among thyroid-based fat loss agents — not as a replacement for T3's precision and potency, but as a pharmacologically more forgiving alternative suited to longer cutting blocks, users with lower cardiovascular tolerance for acute thyroid receptor stimulation, and protocols where stable serum levels over 8–12 weeks outweigh the advantage of week-by-week dose adjustability. At 50 mcg per tablet, the pack allows gradual titration from a single-tablet starting dose through to the 200 mcg/day performance ceiling without the arithmetic complexity of splitting smaller tablets. Used correctly — fasted dosing, weekly heart rate checks, an AAS base at higher doses, and a confirmed post-cycle bloodwork sign-off — T4 remains a reliable and well-tolerated metabolic tool for the cutting phases carried by Steroid Warehouse.

References